Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present ADMA Biologics Inc (NASDAQ: ADMA).

Full DD Report for ADMA

You must become a subscriber to view this report.


Recent News from (NASDAQ: ADMA)

ADMA Biologics granted U.S. Patent for treating respiratory infections
United States Patent and Trademark Office has issued ADMA Biologics (NASDAQ: ADMA ) U.S. Patent No. 9,969,793 covering methods of treating respiratory infections. More news on: ADMA Biologics Inc, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 16 2018 08:42
ADMA Biologics Granted U.S. Patent for Treating Respiratory Infections
RAMSEY, N.J. and BOCA RATON, Fla., May 16, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”) today announced that the United States Patent and Trademark Office issued to the Company U.S. Patent No. 9,969,793 covering methods of...
Source: GlobeNewswire
Date: May, 16 2018 07:30
ADMA Biologics Reports First Quarter 2018 Financial Results
RAMSEY, N.J. and BOCA RATON, Fla., May 14, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), today announced its financial results for the quarter ended March 31, 2018 and provided an update on its operations and corporate obj...
Source: GlobeNewswire
Date: May, 14 2018 17:05
ADMA Bio retires 8.6M shares of stock issued to Biotest; shares up 10%
ADMA Biologics ( ADMA +10.2% ) announces that it has negotiated the receipt and retirement of ~8.6M shares of its non-voting common stock previously issued to Biotest Pharmaceuticals (BPC) for its Therapy Business Unit (12.9M total ADMA shares issued). More news on: ADMA Biologics Inc,...
Source: SeekingAlpha
Date: May, 14 2018 14:08
ADMA Biologics Retires Approximately 8.6 Million Shares Previously Issued to Biotest
RAMSEY, N.J. and BOCA RATON, Fla., May 14, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”) announced today that it has negotiated the receipt and immediate retirement of approximately 8.6 million shares of its non-voting comm...
Source: GlobeNewswire
Date: May, 14 2018 13:17
ADMA Biologics Announces the Release of its First Commercial Batch of Nabi-HB Manufactured Under its Ownership
RAMSEY, N.J. and BOCA RATON, Fla., April 24, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), today announced that it has successfully completed the manufacturing, release and has made commercial sales of its first batch of N...
Source: GlobeNewswire
Date: April, 24 2018 07:28
Institutional Top Ideas Series: Broadfin Capital
In the last entry of this recently rebooted series, we took a look at top ideas from Deerfield Management (whose performance almost doubled that of the IBB during time frame we looked at). Keep in mind articles older than 10 days can only be accessed if you have a membership to ROTY or S...
Source: SeekingAlpha
Date: April, 05 2018 12:11
Institutional Top Ideas Series: Consonance Capital
The last time I did this series was in August of last year, so it has been quite a while. In the past we took a look at portfolios of institutional investors of note, such as BVF, Opaleye, Great Point Partners, Consonance Capital and more. With this reboot, I hope to again delve into the po...
Source: SeekingAlpha
Date: March, 23 2018 13:07
ADMA Biologics: Almost Ready To Run Between The Toes Of Giants
1. Introduction to the Investment Thesis ADMA Biologics is a sub-$100m capitalization healthcare company that is based in Boca Raton, Florida. The company is aiming to commercialize a novel high-titer hyper-immune globulin product for the treatment of RSV and related respiratory viruses...
Source: SeekingAlpha
Date: March, 06 2018 07:36
ADMA Biologics reports FY results
ADMA Biologics (NASDAQ: ADMA ): FY EPS of -$1.91 More news on: ADMA Biologics Inc, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: March, 05 2018 07:11

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-175.145.425.55695.1241466,540
2017-06-203.143.00013.142.9747,256
2017-06-193.053.0343.053.000133,765
2017-06-163.1693.0453.16992.9691,553
2017-06-153.133.183.183.069729,121

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1469,159152,42545.3725Short
2018-08-1330,54646,27166.0154Short
2018-08-1074,381128,46957.8980Short
2018-08-0958,237125,27446.4877Short
2018-08-0821,51459,00336.4626Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ADMA.


About ADMA Biologics Inc (NASDAQ: ADMA)

Logo for ADMA Biologics Inc (NASDAQ: ADMA)

ADMA Biologics is a late stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma based biologics for the treatment and prevention of certain infectious diseases. Our targeted patient populations include immune compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune suppressed for medical reasons. Our product candidates are intended to be used by physician specialists focused on caring for immune compromised patients with infectious diseases. ADMA also operates ADMA BioCenters, an FDA licensed, GHA certified source plasma collection facility which provides a portion of blood plasma for the manufacture of the our lead product candidate RI .

 

Contact Information

 

 

Current Management

  • Adam S. Grossman / President, CEO, Founder
    • Mr. Grossman has been a director of ADMA since , has served as ADMA s President and Chief Executive Officer since October and as ADMA s President and Chief Operating Officer between and October . Mr. Grossman has over years experience in the blood and plasma industry. Prior to founding ADMA, Mr. Grossman was the Executive Vice President of National Hospital Specialties and GenesisBPS, a position he held between and . He has experience in launching new products, building and managing national and international sales forces, managing clinical trials, and completing numerous business development transactions. Previously, he worked at MedImmune, Inc., where he worked on marketing teams for RSV and CMV immunoglobulins, and at the American Red Cross, where he launched new products with the Biomedical Services division. Mr. Grossman received a B.S. in Business Administration, with a specialization in International Business and Marketing, from American University. Mr. Grossman is the son of Dr. Jerrold B. Grossman, our Vice Chairman. Mr. Grossman was chosen to serve on the Board of Directors because, as ADMA s Chief Executive Officer, he is able to provide the Board with critical insight into our daytoday operations.
  • Brian Lenz / CFO
  • Steven A. Elms / Chairman
    • Mr. Elms serves as a Managing Partner at Aisling Capital, which he joined in . Previously, he was a Principal in the Life Sciences Investment Banking Group of Hambrecht amp Quist. During his five years at Hambrecht amp Quist, Mr. Elms was involved in over financing and merger and acquisition transactions, helping clients raise in excess of . billion in capital. Prior to joining Hambrecht amp Quist, Mr. Elms traded mortgagebacked securities at Donaldson, Lufkin amp Jenrette. His previous healthcare sector experience includes over two years as a pharmaceutical sales representative for Marion Laboratories and two years as a consultant for The Wilkerson Group. Mr. Elms received a B.A. in Human Biology from Stanford University and an M.B.A. from Kellogg Graduate School of Management at Northwestern University. Mr. Elms serves on the boards of Ambit Biosciences Corporation, Pernix Therapeutics Holdings, Inc. and a number of other private companies. Mr. Elms was chosen to serve on the Board of Directors because of his valuable experience in the investment and investment banking industry, particularly with respect to strategic and financing transactions.
  • Adam S. Grossman / Director
    • Mr. Grossman has been a director of ADMA since , has served as ADMA s President and Chief Executive Officer since October and as ADMA s President and Chief Operating Officer between and October . Mr. Grossman has over years experience in the blood and plasma industry. Prior to founding ADMA, Mr. Grossman was the Executive Vice President of National Hospital Specialties and GenesisBPS, a position he held between and . He has experience in launching new products, building and managing national and international sales forces, managing clinical trials, and completing numerous business development transactions. Previously, he worked at MedImmune, Inc., where he worked on marketing teams for RSV and CMV immunoglobulins, and at the American Red Cross, where he launched new products with the Biomedical Services division. Mr. Grossman received a B.S. in Business Administration, with a specialization in International Business and Marketing, from American University. Mr. Grossman is the son of Dr. Jerrold B. Grossman, our Vice Chairman. Mr. Grossman was chosen to serve on the Board of Directors because, as ADMA s Chief Executive Officer, he is able to provide the Board with critical insight into our daytoday operations.

Current Share Structure

  • Market Cap: $238,368,703 - 05/14/2018
  • Authorized: 75,000,000 - 12/31/2012
  • Issue and Outstanding: 45,317,244 - 03/09/2018

 


Recent Filings from (NASDAQ: ADMA)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 14 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 14 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: May, 03 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: April, 27 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 24 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 29 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 05 2018

 

 


Daily Technical Chart for (NASDAQ: ADMA)

Daily Technical Chart for (NASDAQ: ADMA)


Stay tuned for daily updates and more on (NASDAQ: ADMA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ADMA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ADMA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ADMA and does not buy, sell, or trade any shares of ADMA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/